Mükoz membran pemfigoidi – bir olgu sunumu

Mükoz membran pemfigoid MMP kronik, enflamatuar, subepiteliyal veziküllo-büllöz bir otoimmün hastalıktır. Hastalığın lezyonları oral mukozayı, oküler mukozayı,diğer muköz membranları ve deriyi kapsayabilir. Ağız lezyonların haricindeki lezyonların iyileşmesi skarla sonuçlanır. Göz tutulumu körlükle sonuçlanabilir. Oral mukozadan sonra en sık tutulan bölge konjuktiva olduğu için bu hastalarda mutlaka oftalmolojik konsültasyon ve takip yapılmalıdır. MMP’in tedavisi multdisipliner bir yaklaşım gerektirir. Erken teşhis ve tedavisi hastalığa bağlı komplikasyonları önleyebilir. Lezyonları sadece ağız içinde olan hastalar “düşük riskli” hasta grubu olarak tanımlanır. Günümüzde düşük riskli hasta grubu sistemik kortikosteroidlere göre daha etkili ve daha az yan etkileri olan topikal kortikosteroidlerle tedavi edilebilir. TS’lerin etkinliği ilacın gücüne, konsantrasyonuna, ilacın farmasötik şekline ve ilaç – lezyon temas süresine bağlıdır. Hastanın medikal durumu, ağız içi lezyonların şiddeti, tutulumun yaygınlığı ve hekimin deneyimi oral mukozada sınırlı kalan MMP’nin tedavisinde kullanılacak TS’nin potensinin, özel formülasyonun ve tedavi rejiminin seçimini etkiler. Bu raporda 59 yaşında MMP’li bir kadın hastanın kliniği ve topikal steroidlerle yapılan tedavisi sunulmaktadır.

Anahtar Kelimeler:

muköz membran pemfigoidi, topikal kortikosteroidler, oral mukoza

Mucous Membrane Pemphygoid A Case Report

Mucous membrane pemphigoid MMP is an otoimmun, cronic, inflamatuary, blastering disease. Its clinical presentation may cover the oral mucosa, the ocular mucosa, the other mucous membrane and the skin. Healing of the lesions, except the lesions of oral mucosa, occurs with skar tissue which may cause blindness when involves the conjuctiva. Ocular mucosa is the most involved mucousa after oral mucosa. Ophtalmologic consultation and following up of this patients is necessary. A multidisciplinary approach is essential in the managenet of MMP. Early recognition and treatment may decrease disease-related complications. Patients who have disease occuring in only oral mucosa are defined as “low risk” patients. Nowadays, low group patients can be controlled by topical corticosteroids TC , which have proved to be highly efficient and to cause fewer adverse effects compared with systemic corticosteroids. The effect of TC depends on its potency, concentration, pharmaceutical form and contact time between the drug and lesion. The medical status of the patient, the severity of the oral lesions, the extensiveness of the lesion and the experience of the clinician affect the choice of the special formulation, treatment regime and the potency of TCs which will be used in treatment of MMP limited in the oral mucosa. In this report clinical view of a 59 years old female patient with MMP who is treated with corticosteroids is presented

Keywords:

mucous membrane pemphygoid, topical corticosteroids, oral mucosa,

PDF

___

1. Nelson BL, Thompson LDR.Oral cicatrial pemphigoid.Oral Surg Oral Med Oral Pathol 1993; 76: 453-9
2. Chan LS.Mucous Membrane Pemphigoid.Clinics in Dermatology 2001; 19: 703- 711
3. Sami N, Bhol KC, Ahmed AR. Intravenous Immunoglobulin Therapy in Patients with Multiple Mucosal Involvement in Mucous Membrane Pemphigoid.Clin Immunology 2002; 102: 59-67
4. Marx RE, Stern D.Immune-Based Diseases.In:editor Bywaters LC.Oral and Maxillofacial Pathology.A Rationale for Diagnosis and Treatment.2003.Chapter 3: 148- 53
5. Leao JC, Ingafou M,Khan A,Scully C, Porter S.Desquamative gingivitis: retrospective analysis of disease associations of a large cohort.Oral Dis 2008; 14: 556-60
6. MOSTAFA MI, HASSIB NF,NEMAT AH. Case Report.Oral mucous membrane pemphigoid in a 6-year-old boy: diagnosis, treatment and 4 years follow-up.Int J of Paediatric Dentistry 2009; 76-9
7. Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid.Ophtalmol 2004; 111: 45-52
8. Ahmed AR, Kurgis BS, Rogers III RS. Cicatricial pemphigoid. J Am Acad Dermatol 1991; 24: 987-1001
9. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43: 571-91
10. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang – Xuan T, Kirtsching G, Korman NJ, Lightman S, Lozada – Nur F, Marinkovich P, Mondino BJ, Prost – Scuarcioni C, Rogers III RS, Setterfield JF, West DP, Wojnarowska F, Woodley DT, Yancey KM, Zillikens D, Zone JJ. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-9
11. Yeh SW, Ahmed B, Sami N, Razzaque Ahmed A. Blistering disorders: diagnosis and treatment. Dermatol Ther 2003; 16: 214-23
12. Sollecito TP,Parisi E. Mucous membrane pemphigoid. Dent Clin N Am 2005; 49: 91-106
13. Mobini N, Nagarwalla N ,Ahmed AR. Oral pemphigoid.Subset of cicatrial pemphigoid? Oral Surg Oral Med Oral Pathol 1998; 85: 37-43
14. Scully C, Muzio LL. Oral mucosal diseases: Mucous membrane pemphigoid. Br J Oral andMaxillofac Surg 2008; 46: 358-366
15. Alkan A, Gunhan O ,Otan F.A. Clinical study of oral mucous membrane pemphigoid. J Int Med Res 2003; 31: 340-4
16. Helander SD, Rogers III RS.The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol 1994; 30: 65-75
17. Scott JE, Ahmed AR. The blistering diseases. Med Clin North Am 1998; 82: 1239- 83
18. Suresh L and Kumar V. Significance of IgG4 in the diagnosis of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol 2007; 104: 359-62
19. Neff AG, Turner M, Mutasim DF. Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag 2008; 4: 617-26
20. Higgins GT, Allan RB, Hall R, Field EA, Kaye SB. Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa. Br J Ophtalmol 2006; 90: 964- 67
21. Ciarrocca KN,Greenberg MS.A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol 1999; 88: 159- 63
22. Arash A, Shirin L.The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid.J Oral Pathol Med 2008; 37: 341-44
23. Gonzalez-Moles MA, Scully C. Vesiculo-erosive Oral Mucosal DiseaseManagement with Topical Corticosteroids: (1) Fundamental Principles and Specific Agents Abailable. J Dent Res 2005; 84:294-301
24. Heffernan MP, Bentley DD. Successful Treatment of Mucous Membrane Pemphigoid With Infliximab. Arch Dermatol 2006; 142: 1268-70
25. Kayalap S.O. Rasyonel Tedavi Ynünden Tıbbi Farmakoloji. 10. Baskı Hacettepe – Tıp. 2002; 1230-50